Bioversys
PublicBioversys is now publicly traded
The data on this page reflects Bioversys's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Feb 7, 2025
Last Round
Strategic
Sep 11, 2024
Total Funding Raised
$210.09M
Company Overview
BioVersys is a biotechnology company specializing in the research and development of small molecules targeting novel bacterial infections to provide new treatment options for life-threatening antibiotic-resistant conditions.
Sector
Biotech
AI Layer
Non-AI
Keywords
Bioversys Comparables
Compare Bioversys with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| VenatoRx Pharmaceuticals | 76% | |
| Trellis Bioscience | 70% | |
| Macrolide Pharmaceuticals | 69% |
Bioversys Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| IPO | Feb 7, 2025 | ||||
| Strategic | Sep 11, 2024 | ||||
| Series C Extension | May 7, 2024 | ||||
| Series C Extension | Jan 5, 2023 | ||||
| Series C | Jun 8, 2022 | ||||
Grant | Jun 1, 2021 |
Bioversys Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| AMR Action Fund | Series C Extension, IPO, Series C |
| CR Ventures | Series C |
| EVA – the Basel life sciences start-up agency | Seed |
| CARB-X | Grant |
| Bundesministerium für Bildung und Forschung | Grant |
| Innovative Health Initiative | Grant |
| Citigroup Global Markets Limited | IPO |
Bioversys Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access